Search results
Showing 646 to 660 of 870 results for score
Evidence-based recommendations on holmium laser prostatectomy. This involves using heat from a laser to break down the extra tissue in the prostate.
View recommendations for HTG5Show all sections
Balloon dilation for chronic eustachian tube dysfunction (HTG534)
Evidence-based recommendations on balloon dilation for chronic eustachian tube dysfunction in adults and children. This involves using a balloon filled with saline to widen the eustachian tube.
View recommendations for HTG534Show all sections
Evidence-based recommendations on catheterless oesophageal pH monitoring. This involves placing a small wireless capsule in the gullet to check the level of acid.
View recommendations for HTG121Show all sections
Sections for HTG121
This guideline covers the recognition, diagnosis and early management of suspected sepsis in pregnant or recently pregnant people. It includes recommendations on recognition and early assessment, initial treatment, escalating care, finding and controlling the source of infection, early monitoring, information and support, and training and education.
Autism spectrum disorder in adults: diagnosis and management (CG142)
This guideline covers diagnosing and managing suspected or confirmed autism spectrum disorder (autism, Asperger’s syndrome and atypical autism) in people aged 18 and over. It aims to improve access and engagement with interventions and services, and the experience of care, for people with autism.
Cardiovascular disease prevention: primary prevention with lifestyle changes (IND228)
This indicator covers the percentage of patients with a cardiovascular disease risk assessment score of 10% or more identified in the preceding 12 months who are offered advice and support for smoking cessation, safe alcohol consumption, healthy diet and exercise within 3 months of the score being recorded. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM210
Evidence-based recommendations on sacituzumab govetican (Trodelvy) for treating unresectable, triple-negative locally advanced or metastatic breast cancer in adults after 2 or more systemic therapies, at least 1 of which was for advanced disease.
Teriflunomide for treating relapsing–remitting multiple sclerosis (TA303)
Evidence-based recommendations on teriflunomide (Aubagio) for treating relapsing–remitting multiple sclerosis in adults.
Evidence-based recommendations on ranibizumab (Lucentis) for treating visual impairment caused by macular oedema secondary to retinal vein occlusion in adults.
Lateral interbody fusion in the lumbar spine for low back pain (HTG431)
Evidence-based recommendations on lateral interbody fusion in the lumbar spine for low back pain in adults. This involves removing the damaged disc and fixing parts of the spine together, to relieve pain.
Evidence-based recommendations on DyeVert Systems for reducing the risk of acute kidney injury in coronary and peripheral angiography.
This guide describes the process NICE uses to develop indicators from NICE quality standards, NICE guidance or other sources of high-quality evidence
NICE has developed a medtech innovation briefing (MIB) on digital technologies for the detection of melanoma .
This quality standard covers testing, diagnosing and managing hepatitis B in adults, young people and children (from birth). It describes high-quality care in priority areas for improvement.
View quality statements for QS65Show all sections
Sections for QS65
- Quality statements
- Quality statement 1: Testing and vaccination for hepatitis B
- Quality statement 2: Referral for specialist care
- Quality statement 3: Referral to and assessment by specialist care for pregnant women who are identified as hepatitis B surface antigen-positive at antenatal screening
- Quality statement 4: Complete course of neonatal hepatitis B vaccination and blood testing at 12 months
- Quality statement 5: Personalised care plan
- Quality statement 6: Monitoring people with chronic hepatitis B infection who do not meet the criteria for antiviral treatment
- Quality statement 7: 6-monthly surveillance testing for hepatocellular carcinoma in adults with chronic hepatitis B infection who have significant liver fibrosis or cirrhosis
This quality standard covers care and treatment for adults (aged 18 and over) with type 1 diabetes. It describes high-quality care in priority areas for improvement.
View quality statements for QS208Show all sections
Sections for QS208
- Quality statements
- Quality statement 1: Structured education programmes
- Quality statement 2: Continuous glucose monitoring
- Quality statement 3: Statin therapy for primary prevention of cardiovascular disease
- Quality statement 4: 9 key care processes
- Quality statement 5: Assessing the risk of diabetic foot problems on admission to hospital
- Quality statement 6: Support to self-manage diabetes during inpatient admissions
- Quality statement 7 (placeholder): Identification of eating disorders in adults with type 1 diabetes